Literature DB >> 2114950

Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.

P P Lee1, R L Schilsky.   

Abstract

The clinical formulation of leucovorin (5-CHO-FH4) is a mixture of diastereoisomers with markedly different pharmacologic properties. Comparatively little information is available concerning the cellular pharmacology of reduced folate stereoisomers, due largely to the difficulty in preparing sufficient quantities of these compounds for in vitro use. Recent improvements in HPLC technology have now facilitated this process, enabling studies of folate stereochemistry on a larger scale. Using purified (6R) and (6S) leucovorin, we examined the effects of these compounds on the enzymatic activity of Lactobacillus casei thymidylate synthase (TS) in a cell-free system. The natural (6S), unnatural (6R), and racemic (6R,S) leucovorin preparations inhibited TS activity by 50% at concentrations of 0.11, 2.1, and 0.52 mM, respectively. Dixon plots demonstrated the inhibition to be competitive, with Ki values of 85 microM, 1.59 mM, and 385 microM for (6S), (6R), and (6R,S) leucovorin, respectively. In view of the high doses of leucovorin given clinically and the slow clearance of the unnatural isomer, our observations suggest that leucovorin may have important direct inhibitory effects on folate-requiring enzymes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114950     DOI: 10.1007/bf02897229

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  30 in total

1.  Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate.

Authors:  A J WAHBA; M FRIEDKIN
Journal:  J Biol Chem       Date:  1961-03       Impact factor: 5.157

2.  Properties of thymidylate synthetase from dichloromethotrexate-resistant Lactobacillus casei.

Authors:  T C Crusberg; R Leary; R L Kisliuk
Journal:  J Biol Chem       Date:  1970-10-25       Impact factor: 5.157

3.  Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft.

Authors:  S Radparvar; P J Houghton; J A Houghton
Journal:  Biochem Pharmacol       Date:  1989-01-15       Impact factor: 5.858

4.  Inhibition of thymidylate synthetase and dihydrofolate reductase by naturally occurring oligoglutamate derivatives of folic acid.

Authors:  M Friedkin; L T Plante; E J Crawford; M Crumm
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

5.  Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil.

Authors:  M B Yin; S F Zakrzewski; M T Hakala
Journal:  Mol Pharmacol       Date:  1983-01       Impact factor: 4.436

6.  A convenient procedure for purification of thymidylate synthase from L1210 cells.

Authors:  C K Banerjee; L L Bennett; R W Brockman; B P Sani; C Temple
Journal:  Anal Biochem       Date:  1982-04       Impact factor: 3.365

Review 7.  High-dose methotrexate: a critical reappraisal.

Authors:  S P Ackland; R L Schilsky
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

8.  Inhibition of thymidylate synthetase by some analogs of tetrahydrofolic acid.

Authors:  K Slavik; S F Zakrzewski
Journal:  Mol Pharmacol       Date:  1967-07       Impact factor: 4.436

9.  Factors affecting substrate binding in Lactobacillus casei thymidylate synthetase as studied by equilibrium dialysis.

Authors:  J H Galivan; G F Maley; F Maley
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

10.  Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography.

Authors:  K E Choi; R L Schilsky
Journal:  Anal Biochem       Date:  1988-02-01       Impact factor: 3.365

View more
  5 in total

1.  Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; A E Sieder; G Locker; M F Gnant; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

2.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.

Authors:  N J Meropol; N J Petrelli; Y M Rustum; M Rodriguez-Bigas; L E Blumenson; C Frank; E Berghorn; P J Creaven
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

4.  Comparative effect of 6S, 6R and 6RS leucovorin on methotrexate rescue and on modulation of 5-fluorouracil.

Authors:  J Zittoun; J Marquet; J J Pilorget; C Tonetti; E De Gialluly
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

5.  Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer.

Authors:  Helena Taflin; Elisabeth Odin; Kristoffer Derwinger; Göran Carlsson; Bengt Gustavsson; Yvonne Wettergren
Journal:  Cancer Chemother Pharmacol       Date:  2018-09-29       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.